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Stress and stress-associated high levels of glucocorticoid hormones are well-known risk 
factors in the development of drug addiction and vulnerability to relapse (Koob & Kreek, 
2007; Koob, 2008). Human studies indicated that addicts often use drugs to relive their 
stress and anxiety. Moreover, psychological stress is known to increase vulnerability to 
addiction. This „self treatment” may initially decrease stress-evoked adverse effects, 
however, chronic exposure to addictive compounds leads to tolerance and paradoxically, 
drug withdrawal or cessation of the treatment results in serious stress reaction and may 
lead to development of anxiety disorders that is often followed by relapse. Even after long 
periods of abstinence, adverse stressful life events or exposure to chronic stress may 
precipitate relapse.  
In the framework of this grant, we have revealed some important details of the 
cellular and molecular basis of the complex interaction between brain stress system 
and the reward system. 
 
Corticotropin-releasing hormone (CRH)- the neuropeptide and neurotransmitter of 
the neuroendocrine- and brain stress system 
 
The hypothalamic paraventricular nucleus (PVN) contains hypophyseotropic parvocelllar 
neurosecretory neurons provide corticotropin-releasing hormone (CRH) to the pituitary 
portal circulation to initiate the neuroendocrine stress response by stimulating ACTH 
release from the pituitary and consequently glucocorticoid secretion from the adrenal cortex 
(Vale et al., 1981; Swanson et al., 1983; Sawchenko & Swanson, 1985).   
We have confirmed activation of the hypothalamo-pituitary-adrenocortical axis 
during morphine withdrawal by revealing increased levels of CRH mRNA in the 
hypothalamus of rats that have been chronically exposed to morphine and injected 
with naloxone to precipitate withdrawal (Pinter-Kubler et al., 2013). During these 
experiments we have revealed that the activation of CRH transcription in the 
hypothalamus is rather quick: starting 15 min after withdrawal and lasting for about 2 
hours. Furthermore, as reported previously, elevated concentrations of ACTH and 
corticosterone were also noted in all of our recent studies as well (Nunez et al., 2010; 
Martin et al., 2012; Pinter-Kubler et al., 2013). We have also noted significant 
activation of prolactin secretion during naloxone precipitated morphine withdrawal 
that has not reported before {Pinter-Kubler, 2013 #8615).  
 
Regulation of CRH expression in the hypothalamic neurosecretory neurons is rather 
complex and involves different cis-acting elements and trans-acting factors. We have 
previously shown that phosphorylation of cAMP-response element binding protein (CREB) 
plays a role in stress-induced activation of CRH expression in the hypothalamic 
paraventricular nucleus (Kovacs & Sawchenko, 1996). Although pCREB has been widely 
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used as a marker of the activation of CREB-mediated gene transcription, recent evidence 
suggested requirement of additional co-activators that control the kinetics of CREB target 
gene regulation (Liu et al., 2008). Recent research highlighted the transducers of regulated 
CREB activity (TORCs) as such cofactors which facilitate CREB-mediated gene 
transcription (Conkright et al., 2003). TORCs are maintained in an inactive state in the 
cytoplasm as a result of phosphorylation. Different stimuli lead to TORC dephosphorylation 
and subsequent nuclear accumulation, whereby it can freely associate with CREB. 
In the experiments under this grant we have shown phosphorylation of CREB in the 
PVN in morphine-dependent rats during drug withdrawal which may contribute to the 
rapid induction of CRH transcription. Furthermore, it has been revealed that 
activation of CRH transcription in the neurosecretory cells of the PVH was 
accompanied by decrease of phospho-TORC-1 levels in the very same neuron 
population. It should also be noted that withdrawal-induced dephosphorylation of 
TORC-1 was dependent on the noradrenergic inputs originating from the brainstem 
similar to that seen in case of CREB phosphorylation and hypothalamic CRH 
transcription and HPA axis activation (Martin et al., 2012).  
 
CREB phosphorylation contributes to transcriptional activation of many other target genes 
which have cAMP-response element (CRE) (Montminy et al., 1990). Foremost among these 
genes is c-fos. c-fos is induced by extracellular stimuli and encodes c-Fos protein, which is 
a part of AP-1 transcription factor. AP-1 is involved in regulation of various neuropeptides 
implicated in stress- and metabolic regulation as well as in drug addiction via long-term 
changes in neuronal phenotype (Hoffman & Lyo, 2002; Kovacs, 2008). Although acute 
morphine administration and naloxone precipitated withdrawal in morphine dependent rats 
results in a transient elevation of c-fos expressionin various hypothalamic and 
extrahypothalamic sites, these short-lasting alterations may not be responsible for those 
dramatic changes that are seen in the behavior and physiology of addicted animals 
(Laorden et al., 2002). In contrast to other members of the Fos family, ∆FosB is modestly 
induced in the brain after acute drug administration, but because of its unusual long half-life 
persists for weeks, even months, after the cessation of drug use. As a result, it gradually 
accumulates with chronic drug exposure, suggesting that ∆FosB could represent a 
mechanism by which drugs of abuse produce lasting changes in gene expression pattern 
long after the drug is withdrawn (Nestler & Aghajanian, 1997; Nestler, 2004) . The 
expression of ∆FosB in the brain reward system after chronic drug exposure has been 
widely studied (Nye & Nestler, 1996; Nestler, 2001). It has been shown that repeated 
administration of cocaine, amphetamine, cannabinoids or morphine increases ∆FosB levels 
in the nucleus accumbens (NAc) and dorsal striatum (Nestler, 2001; 2004). Given that 
∆FosB is a transcription factor, it may causes behavioral plasticity through alterations in the 
expression of other genes (Nestler & Aghajanian, 1997). 
For the first time, we have provided evidence that chronic morphine exposure results 
in FosB/ ∆FosB accumulation in the stress-related brain circuitry (Nunez et al., 2010). 
Our data thus indicate that neuroadaptation to addictive substances such as 
morphine, observed as accumulation of ∆FosB is not limited to the reward system 
but manifest in other brain regions, such as the brain stress system, which have 
been proposed to be directly related to addiction.  
Various immunochemical (Western blot and immunocytochemistry) techniques were 
applied to identify accumulation of ∆FosB in the hypothalamus, bed nucleus of stria 
terminalis (BNST), central amygdala (CeA) and nucleus of the tractus solitarius (NTS) 
following chronic morphine administration and withdrawal.  Using combinations of 
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immuncytochemical identification of ∆FosB and neuropeptide markers we have 
revealed accumulation of ∆FosB in CRH synthesizing parvocellular neurosecretory 
neurons of the PVN of morphine dependent rats. Furthermore, naloxone-precipitated 
morphine withdrawal also resulted in an increase of double labeled profiles in the 
PVN. Most notably, we have detected ∆FosB immunoreactivity in the tyrozine 
hydroxylase (TH) containing A1 neuron population in the brainstem that provides the 
well-characterized noradrenergic input the stress-related CRH containing 
hypothalamic neurons (Nunez et al., 2010).  
 
Within the brain, expression of corticotropin-releasing hormone, CRH is not limited to the 
hypophyseotropic neurons of the hypothalamic paraventricular nucleus. Additional neuron 
populations such as cell groups in the bed nucleus of stria terminalis and central amygdala, 
as well as neurons in the Barrington’s nucleus, scattered cells in the cortex and in the 
olfactory bulb are also able to synthesize CRH (Swanson et al., 1983) for recent review, see 
(Kovacs, 2013). These neurons provide extrahypothalamic CRH that have been implicated 
as neurotransmitter and/or neuromodulator upon binding to CRH1R and to lesser extent to 
CRH2R receptors (Lu et al., 2000; Kuperman & Chen, 2008). Among these CRH containing 
areas, cells in the “extended amygdala” (BNST and CeA) are of pivotal importance in 
mediating behavioral and emotional responses to various stress challenges including those 
that are related to drug addiction (Kiefer & Wiedemann, 2004).  
In the framework of this international collaboration grant, we confirmed previous 
findings that morphine addiction results in long term neuronal plasticity in the 
extended amygdala (nucleus accumbens shell: sNAc, BNST and CeA), via expression 
of ∆FosB. Our research groups were the first, however, to reveal that CRH cells in the 
CeA and BNST became activated and express ∆FosB in morphine dependent animals 
and during morphine withdrawal. Furthermore, using unbiased quantitative analysis 
of CRH immunostained material, we have provided evidence that the number of CRH 
positive profiles is increased in the BNST (but not in the CeA) during morphine 
withdrawal. ∆FosB accumulation in the extended amygdala occurred in parallel with 
∆FosB appearance in the TH neurons in the origin of ascending catecholaminergic 
pathways that innervate PVH and BNST/CeA and might be implicated in the negative 
emotional state during drug withdrawal (Nunez et al., 2010).  
 
It is very important to note that CRH gene expression is differentially regulated in the PVN 
and in the extended amygdala (Watts, 2005). CRH neurons in the hypophyseotropic cells of 
hypothalamus are under negative feedback effect of glucocorticoids via their direct or 
indirect action through TypeII glucocorticoid receptors (GR). By contrast, CRH transcription 
in the CeA and BNST is increased upon exposure to stress-levels of corticosteroid 
hormones (Watts & Sanchez-Watts, 1995; Kovacs, 2013). Although the cellular/molecular 
mechanism of facilitatory glucocorticoid action on CRH expression in the extended 
amygdala remained unresolved, the phenomenon is highly implicated in the negative 
emotional, physiological and behavioral state that seen during withdrawal in response to 
highly increased glucocorticoid discharge (McNally & Akil, 2002). 
To reveal the contribution of hypothalamic vs. amygdala CRH in mediation of 
hormonal-, behavioral- and physiological symptoms of drug withdrawal we have 
designed experiments for site-specific silencing of the CRH gene. These included 
local injections of lentiviral constructs to the hypothalamic PVH or to amygdala of 
morphine dependent rats before withdrawal. Following our negative experience with 
constructs purchased from a company, at the end of 2012, we have started 
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collaboration with Dr. A. Chen’s laboratory (Department of Neurobiology, Weizmann 
Institute of Science, Rehovot, Israel) who reported successful knock down of 
amygdala CRH expression using their own lentiviral constructs (Regev et al., 2012). 
To this end, lentiviral constructs were designed that produce small hairpin (sh)RNA 
to CRH. The results of these experiments are under analysis in our laborytory. 
   
In addition to CRH, some other members of CRF-related neuropeptide family such as 
urocortins (UCN1, UCN2 and UCN3) have also implicated in drug addiction (Koob, 2010). 
CRH and urocortins have differential affinity towards CRF receptors: CRH binds to CRHR1, 
UCN2 and UCN3 display high affinity to CRH2R, while urocortin1 binds to both receptors 
with equal affinity. It is important to note that CRH1R and CRH2Rs play a differential role in 
anxiogenesis activation of type 1 receptors promote anxiety, while type2 receptors have 
opposite effect (van Gaalen et al., 2002; Merali et al., 2003; Muller et al., 2003). However, 
pharmacological blockade of both CRH receptors during morphine withdrawal results in 
decrease of behavioral- affective and physiological but not hormonal withdrawal symptoms 
(Almela et al., 2012). 
To assess the possible role of urocortins in the development of morphine 
dependence and during naloxone precipitated drug withdrawal, we detected by 
quantitative real time PCR the mRNA levels of UCN2 and UCN3 in the hypothalamus 
and found a significant increase of UCN2 but not UCN3 during withdrawal (Pinter-
Kubler et al., 2013).  
 
Involvement of metabolic and reward-related neuropeptides in morphine dependence 
and withdrawal 
 
Morphine dependence and naloxone-precipitated morphine withdrawal results in specific 
changes of other neuropeptide genes within the hypothalamus and extrahypothalamic 
brain sites that are involved in the stress- metabolic and behavioral regulation.  
For instance, orexins have recently been hypothesized to modulate the extended amygdala 
and to contribute to the negative emotional state associated with dependence (Georgescu 
et al., 2003). 
We have revealed that naloxone-precipitated morphine withdrawal activates 
orexinergic neurons in the lateral hypothalamus and increases the expression of 
orexinA mRNA levels.  These orexinergic neurons project to the extended amygdala, 
PVN and NTS areas that are critically involved in the reward and stress regulation. 
However, orexinA activates neurons only in the CeA but not BNST or PVH neurons 
during morphine withdrawal. Orexin1-receptor antagonist (SB334867) attenuates 
somatic but not hormonal withdrawal symptoms in morphine dependent rats. These 
results highlight differential involvement of the brain orexinergic system in 
development of morphine dependence and withdrawal symptoms (Laorden et al., 
2012).  
 
One of the most significant somatic withdrawal symptoms in rats is the dramatic weight loss 
that appears during naloxone-precipitated withdrawal. Morphine-dependent rats loss up to 
20-25% of their body weight shortly after naloxone injection. Morphine dependence has also 
been shown to have significant effect on metabolism. However, the neurobiological 
background of these changes was not resolved.  
During the studies of this international grant we have investigated the metabolic 
status of morphine-dependent rats and changes of metabolic parameters during 
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naloxone precipitated drug withdrawal. Using a pair-feeding paradigm we have 
proved that morphine dependent rats in the first period of dependence loose less 
weight than their pair-fed controls suggesting reduced energy expenditure and/or 
increased metabolic efficiency. Interestingly, changes of the body weight of 
morphine dependent or pair fed animals was not accompanied by any significant 
changes of key hypothalamic neuropeptides involved in stress-and metabolic 
regulation such as NPY, POMC and UCNs.  We have found however, increase of CRH, 
UCN2 and NPY mRNA levels and a very significant decrease of POMC expression in 
the hypothalamus of morphine dependent rats during naloxone-precipitated 
morphine withdrawal. These results suggest differential effects of mu-opioid 
dependent mechanisms in regulation of hypothalamic expression of stress- and 
metabolic-related neuropeptide genes (Ferenczi et al., 2010; Pinter-Kubler et al., 
2013).  
 
In summary, the principal findings of the studies performed in the framework of the 
present OTKA NN grant are the following: 
 
1. Morphine dependence and naloxone-precipitated morphine withdrawal results 
in activation of the neuroendocrine and brain stress systems in the rat brain. 
2. Corticotropin-releasing hormone expressed in the hypophyseotropic cells of 
the hypothalamus as well as in the extended amygdala plays a differential role 
in the development of hormonal, physiological, emotional and behavioral 
changes in addicted animals. 
3. cAMP-response element binding protein (CREB) and its co-activators (such as 
pTORC) play a critical role in activation of corticotropin-releasing hormone 
gene expression both in the hypothalamus and in the extended amygdala. 
4. Ascending noradrenergic and orexinergic pathways innervating hypothalamic 
and extrahypothalamic sites differentially regulate the development of 
hormonal, somatic and psychological symptoms of morphine withdrawal. 
5. Metabolic changes associated by drug dependence and withdrawal result in 
differential changes of metabolic and stress-related neuropeptides in the 
hypothalamus. 
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